Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this narrative review, researchers reported that oral finasteride significantly improved hair count and density in male androgenetic alopecia but had higher systemic exposure and potential side effects compared to topical formulations, which provided similar efficacy with lower systemic DHT suppression.

This article presents a planned trial comparing radiotherapy and imiquimod for lentigo maligna treatment, noting a lack of direct evidence supporting current therapies, and aims to inform future treatment guidelines.

This study reports that perioperative use of dutasteride, both orally and through mesotherapy, may enhance hair graft survival and reduce shock loss in patients undergoing hair transplantation for androgenetic alopecia.

This review reports that while finasteride effectively treats androgenetic alopecia and benign prostatic hyperplasia, persistent adverse effects on sexual, psychological, and metabolic health have been noted, highlighting the need for ongoing research and careful risk assessment for safer clinical usage.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

This review found that dutasteride is more effective than finasteride in increasing hair count and shaft thickness for androgenetic alopecia in men, with potential for reduced systemic side effects through mesotherapy, although further research is needed on long-term safety and dosage.

This review discusses the classifications, diagnostic methods, and treatment strategies for female pattern hair loss, but reports no clinical results.

This study found that Eucommia ulmoides bark extract shows potential antioxidant and hair follicle-support properties in vitro and in vivo, but further validation is needed to confirm these effects.

This study suggests that Terminalia chebula fruit extract may promote hair growth in androgenetic alopecia by activating specific signaling pathways and inhibiting 5α-reductase, showing effectiveness comparable to finasteride.

In this study, using a novel topical androgen receptor suppressor, fluridil, significantly increased the percentage of growing hairs in males with androgenetic alopecia without systemic absorption or adverse side effects.

This article reviews the use of anti-androgens for dermatological conditions linked to androgen involvement and reports encouraging clinical experiences in females, with use in males limited to specific conditions due to toxicity concerns.

This study introduced a novel nonsteroidal androgen receptor antagonist that effectively controls sebum production in the golden Syrian hamster ear model through targeted follicular delivery.

In this study, DHT was found to inhibit hair growth in mice by decreasing IGF-I production in dermal papillae through reduced sensory neuron stimulation.

This study found that dihydrotestosterone (DHT) suppresses prostaglandin E2 and TGF-β induced IGF-I gene promoter activity in osteoblasts, suggesting complex interactions among bone growth regulators and potential complications from anabolic steroid use.

This review discusses the hormonal influences on prostate carcinogenesis and notes ongoing trials investigating whether finasteride could reduce prostate cancer incidence by inhibiting dihydrotestosterone synthesis, but it reports no new results.

This review highlights the potential therapeutic applications of nandrolone, an anabolic steroid, for male health, but notes that more human studies are needed due to limited existing literature.

Scale created to measure hair loss in men and women; MK-386 reduces acne; Niaspan treats dyslipidemia; minoxidil increases heart rate.

This review discusses potential causes of androgenic alopecia and explores treatment options, but provides no new clinical results; it emphasizes considering androgen overproduction syndromes in female patients.

This review discusses nearly 70 patent applications for the treatment of androgenetic alopecia and other hair conditions, highlighting the mechanisms of action explored but reports no clinical results.

This review concludes that finasteride and dutasteride are the most evidence-supported oral treatments for androgenetic alopecia, with dutasteride offering slightly greater hair count improvements and both affected by genetic response modifiers.

This study reviews the effectiveness and safety of finasteride and dutasteride for treating androgenetic alopecia, highlighting that dutasteride reduces DHT more deeply than finasteride, with genetic factors influencing patient response and both drugs being evidence-supported options for men and women.

This review examines the effects of sex hormones on hair growth and the pathogenesis of related hair disorders, highlighting current management benefits and controversies but reporting no new results.

Androgenetic alopecia treatments focus on reducing hair loss by targeting hormones, with new therapies showing promise but needing more research.

Topical finasteride promotes hair growth with minimal side effects but needs more research for women and optimal use.

This study demonstrated that engineered exosomes carrying EGF and FGF restored hair density and follicle integrity in an androgenetic alopecia mouse model by reactivating hair follicle growth factors, offering a novel therapeutic approach without immunogenic reactions or systemic toxicity.

This review discusses the management of androgenic disorders in women, highlighting that treatment is generally more effective than recognized, though improvement may take weeks or months to appear.

The authors concluded that while finasteride 1 mg affects prostate-related pathways, evidence is insufficient to prove clinical benefits for prostate outcomes compared to the established effectiveness of finasteride 5 mg.

This study found that finasteride-loaded microspheres effectively treated androgenic alopecia in a mouse model, showing similar hair growth effects to orally-administered finasteride.

This study found that using isotretinoin and acitretin was not linked to a higher risk or severity of COVID-19 in patients undergoing systemic retinoid therapy.

This article reviews the hormonal and medication-related factors associated with acne development but does not present new research findings.